David S. Arrington
Keine laufenden Positionen mehr
Karriereverlauf von David S. Arrington
Ehemalige bekannte Positionen von David S. Arrington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ACHAOGEN | Investor Relations Kontakt | 01.07.2017 | 01.04.2018 |
Public Communications Contact | 01.07.2017 | 01.04.2018 | |
FREELINE THERAPEUTICS HOLDINGS PLC | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - | |
COHERUS BIOSCIENCES, INC. | Investor Relations Kontakt | 01.09.2018 | - |
Public Communications Contact | 01.09.2018 | - |
Ausbildung von David S. Arrington
Washington State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Vereinigtes Königreich | 2 |
Operativ
Investor Relations Contact | 3 |
Public Communications Contact | 3 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
COHERUS BIOSCIENCES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Börse
- Insiders
- David S. Arrington
- Erfahrung